FFIV Investors Have Opportunity to Lead F5, Inc. Securities Fraud Lawsuit with the Schall Law Firm
prnewswire.com
Want to monitor IBRX?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor IBRXimmunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer (‘nk’) and t cells, tumoricidal macrophages, and memory t cells.